Introduction: With calcineurin inhibitors potentiating damage from ischaemia-reperfusion injury in kidneys from donors after cardiac death we wanted to investigate the role of substituting sirolimus for tacrolimus in the delayed introduction of calcineurin inhibitor regime used in our centre. Method: A prospective randomised paired open-label study was performed taking pairs of kidneys from each donor and randomising one to a tacrolimus-based regime and the other to a similar regime based on sirolimus. Graft function at one year was the primary endpoint. Results: Total 31 pairs of kidneys were randomised to each group, with 19 pairs of recipients available for analysis after post-randomisation study exclusions. Despite a higher incidence of biopsy proven acute rejection in the sirolimus group, renal allograft function was similar in both groups at three-monthly intervals up to one year post-transplant. All episodes of acute rejection in the sirolimus group occurred in the first three months. Graft and patient survival at one year was 100% in the tacrolimus group, with one death with functioning graft in the sirolimus group (95% survival). Unfortunately, 10 of the 19 patients in the sirolimus arm required switch of medication to tacrolimus due to acute rejection or intolerable drug side effects. Conclusions: Graft survival and function were very similar in the two groups despite the higher rate of acute rejection in the sirolimus arm, raising the possibility that the damage done by acute rejection was adequately offset by the nephron-sparing effect of sirolimus compared to tacrolimus. Sirolimus may have a role as a longer-term maintenance immunosuppressant after initial treatment with a different agent such as tacrolimus or belatacept.

Keywords:
Transplantation
1.
Nicholson ML, Metcalfe MS, White SA, Waller JR, Doughman TM, Horsburgh T, Feehally J, Carr SJ, Veitch PS: A comparison of the results of renal transplantation from non-heart-beating, conventional cadaveric and living donors. Kidney Int 2000;58:2585-2591.
2.
Gok MA, Buckley PE, Shenton BK, Balupuri S, El-Sheikh M, Robertson H, Soomro N, Jaques BC, Manas DM, Talbot D: Long-term renal function in kidneys from non-heart-beating donors: a single-center experience. Transplantation 2002;74:664-669.
3.
Gok MA, Asher JF, Shenton BK, Rix D, Soomro NA, Jaques BC, Manas DM, Talbot D: Graft function after kidney transplantation from non-heartbeating donors according to Maastricht category. J Urol 2004;172:2331-2334.
4.
Brook NR, Waller JR, Richardson AC, Bradley JA, Andrews PA, Koffman G, Gok M, Talbot D, Nicholson ML: A report on the activity and clinical outcomes of renal non-heart beating donor transplantation in the United Kingdom. Clin Transplant 2004;18:627-633.
5.
Asher J, Wilson C, Gok M, Balupuri S, Bhatti AA, Soomro N, Rix D, Jaques B, Manas D, Shenton B, Talbot D: Factors predicting duration of delayed graft function in non-heart-beating donor kidney transplantation. Transplant Proc 2005;37:348-349.
6.
Balupuri S, Buckley P, Snowden C, Sen B, Griffiths P, Hannon M, Manas D, Kirby J, Talbot D: The trouble with kidneys derived from the non heart beating donor: a single center 10-year experience. Transplantation 2000;69:842-846.
7.
Pernat A, Weil MH, Sun S, Tang W: Stroke volumes and end-tidal carbon dioxide generated by precordial compression during ventricular fibrillation. Crit Care Med 2003;31: 1819-1823.
8.
Zangwill S, Ellis T, Stendahl G, Zahn A, Berger S, Tweddell J: Practical application of the virtual crossmatch. Pediatr Transplant 2007;11:650-654.
9.
Bingaman AW, Murphey CL, Palma-Vargas J, Wright F: A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation. Transplantation 2008;86:1864-1868.
10.
Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ: The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporin. Am J Surg Pathol 1993;17:60-68.
11.
Randhawa PS, Tsamandas AC, Magnone M, Jordan M, Shapiro R, Starzl TE, Demetris AJ: Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. Am J Surg Pathol 1996;20:306-312.
12.
Curtis JJ: Renovascular elements of the cyclosporin injury. Transplant Proc 1996;28:2094-2096.
13.
Wilson CH, Brook NR, Gok MA, Asher JF, Nicholson ML, Talbot D: Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants. Br J Surg 2005;92:681-687.
14.
Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wramner L, Brattström C, Charpentier: Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporin. Sirolimus European Renal Transplant Study Group. Transplantation 1999;67:1036-1042.
15.
Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J: Sirolimus allows early cyclosporin withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001;72:777-786.
16.
Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andres A, Arenas J, Nègre E, Burke JT, Groth CG: Sirolimus does not exhibit nephrotoxicity compared to cyclosporin in renal transplant recipients. Am J Transplant 2002;2:436-442.
17.
Fuller TF, Freise CE, Serkova N, Niemann CU, Olson JL, Feng S: Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury. Transplantation 2003;76:1594-1599.
18.
Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, Savas K, Cook DJ, Novick AC: Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporin. Transplantation 2002;74:1070-1076.
19.
Ekberg H, Grinyo J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, Truman M, Nasmyth-Miller C, Rashford M: Cyclosporin sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007;7:560-570.
20.
Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E: mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant 2010;24:149-156.
21.
Tiong HY, Flechner SM, Zhou L, Wee A, Mastroianni B, Savas K, Goldfarb D, Derweesh I, Modlin C: A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients. Transplantation 2009;87:296-302.
22.
Goel M, Flechner SM, Zhou L, Mastroianni B, Savas K, Derweesh I, Patel P, Modlin C, Goldfarb D, Novick AC: The influence of various maintenance immunosuppressive drugs on lymphocele formation and treatment after kidney transplantation. J Urol 2004;171:1788-1792.
23.
Flechner SM: Risk factors for and management of sirolimus-associated pneumonitis in kidney transplant recipients. Nat Clin Pract Nephrol 2008;4:250-251.
24.
Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF: Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-2575.
25.
Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP: A phase III study of belatacept-based immunosuppression regimens versus cyclosporin in renal transplant recipients (BENEFIT study). Am J Transplant 2010;10:535-546.
26.
Larsen CP, Grinyo J, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Breshahan B, Campistol JM, Florman S, Rial Mdel C, Kamar N, Block A, Di Russo G, Lin CS, Garg P, Charpentier B: Belatacept-based regimens versus a cyclosporin A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010;90:1528-1535.
27.
Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, Lang P, Urrea EM, Massari P, Mondragon-Ramirez G, Reyes-Acevedo R, Rice K, Rostaing L, Steinberg S, Xing J, Agarwal M, Harler MB, Charpentier : Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012;12: 210-217.
28.
Grinyo J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, Apanovitch AM, Gujrathi S, Agarwal M, Thomas D, Larsen CP: An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010;90: 1521-1527.
29.
Holdaas H, Bentdal O, Pfeffer P, Mjornstedt L, Solbu D, Midtvedt K: Early, abrupt conversion of de novo renal transplant patients from cyclosporin to everolimus: results of a pilot study. Clin Transplant 2008;22:366-371.
30.
Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F: Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011;377:837-847.
31.
Tadesco Silva Jr H, Cibrik D, Johnston T, Lackova E, Mange K, Panis C, Walker R, Wang Z, Zibari G, Kim YS: Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010;10:1401-1413.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.